A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
- Extensive Stage Small Cell Lung Cancer
At a glance
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Amgen
- Enrolment target
- 380
- Started
- 16 September 2025
- Main results due
- 18 March 2028
- Study sites
- 19
- Registry updated
- 25 September 2026
Can you take part?
- Ages 18 years to 90 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: 1. Participant has provided informed consent before initiation of any study-specific activities/procedures. 2. Participants ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent. 3. Participants with histologically or cytologically confirmed ES-SCLC that has progressed or recurred following at least 1 line of anti-cancer therapy for ES-SCLC. 4. Participants must have at least 1 measurable lesion as defined by RECIST 1.1 within 21-day screening period, not previously irradiated. 5. Participants must have adequate organ function (hematological, coagulation, cardiac, pulmonary, kidney, and liver). 6. Participants must submit a fresh tumor biopsy at screening unless a new biopsy cannot be performed safely or is infeasible. Participants who cannot provide fresh tissue may provide archival tissue that was collected after last anticancer therapy. Exclusion Criteria: 1. Symptomatic central nervous system (CNS) metastases. 2. Participants with brain metastases may be eligible if criteria defined in the protocol are met. 3. Prior therapy with any delta-like ligand 3 (DLL3)-directed therapy (including tarlatamab). 4. Prior interleukin (IL)-2, IL-7 or IL-15 targeted therapy. 5. Baseline (at rest) requirement of supplemental oxygen.
What this study is about
In the sponsor’s own words, from the registry.
The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248.
The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.
Study sites(19)
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Terminated
University of Southern California, Norris Comprehensive Cancer Center
Los Angeles, California, United States
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Recruiting
Emory University
Atlanta, Georgia, United States
Recruiting
Norton Cancer Institute - Downtown
Louisville, Kentucky, United States
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Recruiting
Siteman Cancer Center
St Louis, Missouri, United States
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Recruiting
Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, United States
Recruiting
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
Recruiting
Avera Cancer Institute
Sioux Falls, South Dakota, United States
Recruiting
Baptist Cancer Center
Memphis, Tennessee, United States
Recruiting
Swedish Cancer Institute Medical Oncology
Seattle, Washington, United States
Recruiting
Chungbuk National University Hospital
Cheongju Chungbuk, South Korea
Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Recruiting
Severance Hospital Yonsei University Health System
Seoul, South Korea
Recruiting
Adana Sehir Egitim ve Arastirma Hastanesi
Adana, Turkey (Türkiye)
Recruiting
Hacettepe Universitesi Tip Fakultesi Hastanesi
Ankara, Turkey (Türkiye)
Recruiting
Ankara Bilkent Sehir Hastanesi
Ankara, Turkey (Türkiye)
Recruiting
Showing 19 of 19 sites. 18 of the 19 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07037758. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me